Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology
Cancer Letters · 2026-05 · 645 · 218359
DOI: 10.1016/j.canlet.2026.218359 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-05. Verfasst von Suling Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address…. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Melanoma, Precision Medicine, Skin Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 275 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Major Scientific and Technological Project of Zhejiang Province.
Abstract (Originalsprache)
Melanoma remains the most lethal form of skin cancer despite major advances in targeted and immune-based therapies. Biomarkers now play central roles in diagnosis, risk stratification, therapeutic selection, and disease monitoring; however, their clinical integration remains inconsistent. This review synthesizes the evolving biomarker landscape across genetic (e.g., BRAF, NRAS, KIT, TERT, NF1, CDKN2A), immune (PD-L1, LAG-3, TIGIT, TILs, TMB), proteomic (S100B, MMPs, signaling signatures), and digital/imaging biomarkers (AI-assisted dermo copy, spatial and multiplex profiling). We highlight subtype-specific differences in mucosal, acral, and uveal melanoma, where biomarker patterns and therapeutic responses diverge markedly from those of cutaneous disease. Liquid biopsy approaches, including ctDNA, methylation signatures, and extracellular vesicles, are evaluated for minimal residual disease detection and resistance monitoring. To advance clinical translation, we propose a standardized, stepwise diagnostic therapeutic framework integrating tissue- and blood-based biomarkers with AI-enabled imaging to support personalized management in both adjuvant and metastatic settings. Key translational enablers include assay harmonization (PD-L1, TMB, ctDNA), evidence-tiered validation, and pragmatic clinical trials incorporating biomarker-driven endpoints. Addressing cost, accessibility, and data ethics will be essential for biomarker-guided precision oncology to become a sustainable clinical reality across diverse health systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China. Electronic address: xusuling@nbu.edu.cn.
- Department of Dermatology, The First Affiliated Hospital of Ningbo University School of Medicine, Ningbo, Zhejiang, 315020, China.
- Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven, CT, 06510, USA.
- Sanford Stem Cell Institute, Department of Medicine, and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: wma@health.ucsd.edu.
Förderung
- Major Scientific and Technological Project of Zhejiang Province
Zitieren
APA
Xu, S., Huang, Z., Li, Y., Lu, L., & Ma, W. (2026). Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology. Cancer Letters, 645, 218359. https://doi.org/10.1016/j.canlet.2026.218359
Vancouver
Xu S, Huang Z, Li Y, Lu L, Ma W. Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology. Cancer Letters. 2026;645:218359. doi:10.1016/j.canlet.2026.218359
BibTeX
@article{Xu2026,
author = {Xu, Suling and Huang, Zhixing and Li, Yanjun and Lu, Lingeng and Ma, Wenxue},
title = {Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology},
journal = {Cancer Letters},
year = {2026},
volume = {645},
pages = {218359},
doi = {10.1016/j.canlet.2026.218359}
}
EUVIMED